# ADTRAN Holdings, Inc.: financial statements, quarterly

ADTN · Nasdaq · CIK 926282 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/adtn.md) · [Financials](/companies/adtn/financials.md) · [Filings](/companies/adtn/filings.md) · [Insiders](/companies/adtn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/adtn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [272](/filings/0000950170-24-125685.md) | [225 d](/filings/0001193125-26-073878.md) | [226](/filings/0000950170-25-075374.md) | [226](/filings/0000950170-25-102561.md) | [228](/filings/0001193125-25-264157.md) | [243](/filings/0000950170-25-075366.md) | [248](/filings/0001193125-26-205276.md) | [265](/filings/0001193125-26-331632.md) | [279](/filings/0001193125-25-264157.md) | [292 d](/filings/0001193125-26-073878.md) | [286](/filings/0001193125-26-205276.md) | [281](/filings/0001193125-26-331632.md) |
| Cost of revenue | $m | [198](/filings/0000950170-24-125685.md) | [149 d](/filings/0001193125-26-073878.md) | [156](/filings/0000950170-25-075374.md) | [145](/filings/0000950170-25-102561.md) | [145](/filings/0001193125-25-264157.md) | [153](/filings/0000950170-25-075366.md) | [153](/filings/0001193125-26-205276.md) | [166](/filings/0001193125-26-331632.md) | [172](/filings/0001193125-25-264157.md) | [178 d](/filings/0001193125-26-073878.md) | [173](/filings/0001193125-26-205276.md) | [177](/filings/0001193125-26-331632.md) |
| Gross profit | $m | [74.2](/filings/0000950170-24-125685.md) | [76.5 d](/filings/0001193125-26-073878.md) | [70.3](/filings/0000950170-25-075374.md) | [81.3](/filings/0000950170-25-102561.md) | [83.0](/filings/0001193125-25-264157.md) | [89.6](/filings/0000950170-25-075366.md) | [95.2](/filings/0001193125-26-205276.md) | [98.9](/filings/0001193125-26-331632.md) | [107](/filings/0001193125-25-264157.md) | [114 d](/filings/0001193125-26-073878.md) | [113](/filings/0001193125-26-205276.md) | [104](/filings/0001193125-26-331632.md) |
| Research and development | $m | [62.8](/filings/0000950170-24-125685.md) | [54.8 d](/filings/0001193125-26-073878.md) | [60.2](/filings/0000950170-25-075374.md) | [60.4](/filings/0000950170-25-102561.md) | [51.6](/filings/0001193125-25-264157.md) | [49.3](/filings/0000950170-25-075366.md) | [48.9](/filings/0001193125-26-205276.md) | [51.9](/filings/0001193125-26-331632.md) | [51.7](/filings/0001193125-25-264157.md) | [51.8 d](/filings/0001193125-26-073878.md) | [50.8](/filings/0001193125-26-205276.md) | [53.8](/filings/0001193125-26-331632.md) |
| Selling, general and administrative | $m | [62.9](/filings/0000950170-24-125685.md) | [61.7 d](/filings/0001193125-26-073878.md) | [59.0](/filings/0000950170-25-075374.md) | [59.4](/filings/0000950170-25-102561.md) | [57.6](/filings/0001193125-25-264157.md) | [57.0](/filings/0000950170-25-075366.md) | [50.3](/filings/0001193125-26-205276.md) | [60.3](/filings/0001193125-26-331632.md) | [58.2](/filings/0001193125-25-264157.md) | [57.4 d](/filings/0001193125-26-073878.md) | [55.8](/filings/0001193125-26-205276.md) | [60.2](/filings/0001193125-26-331632.md) |
| Operating income | $m | [(89.3)](/filings/0000950170-24-125685.md) | [(40.0) d](/filings/0001193125-26-073878.md) | [(346)](/filings/0000950170-25-075374.md) | [(38.5)](/filings/0000950170-25-102561.md) | [(26.1)](/filings/0001193125-25-264157.md) | [(16.8)](/filings/0000950170-25-075366.md) | [(4.0)](/filings/0001193125-26-205276.md) | [(13.3)](/filings/0001193125-26-331632.md) | [(2.8)](/filings/0001193125-25-264157.md) | [4.5 d](/filings/0001193125-26-073878.md) | [6.4](/filings/0001193125-26-205276.md) | [(10.1)](/filings/0001193125-26-331632.md) |
| Interest expense | $m | [4.5](/filings/0000950170-24-125685.md) | [4.4 d](/filings/0001193125-26-073878.md) | [4.6](/filings/0000950170-25-075374.md) | [6.9](/filings/0000950170-25-102561.md) | [5.7](/filings/0001193125-25-264157.md) | [4.9](/filings/0000950170-25-075366.md) | [4.8](/filings/0001193125-26-205276.md) | [4.6](/filings/0001193125-26-331632.md) | [5.5](/filings/0001193125-25-264157.md) | [4.5 d](/filings/0001193125-26-073878.md) | [4.2](/filings/0001193125-26-205276.md) | [4.2](/filings/0001193125-26-331632.md) |
| Income tax | $m | [(16.6)](/filings/0000950170-24-125685.md) | [64.5 d](/filings/0001193125-26-073878.md) | [(18.6)](/filings/0000950170-25-075374.md) | [2.1](/filings/0000950170-25-102561.md) | [0.4](/filings/0001193125-25-264157.md) | [23.5](/filings/0000950170-25-075366.md) | [(0.4)](/filings/0001193125-26-205276.md) | [1.0](/filings/0001193125-26-331632.md) | [1.2](/filings/0001193125-25-264157.md) | [3.2 d](/filings/0001193125-26-073878.md) | [1.9](/filings/0001193125-26-205276.md) | [0.8](/filings/0001193125-26-331632.md) |
| Net income | $m | [(78.2)](/filings/0000950170-24-125685.md) | [(112) d](/filings/0001193125-26-073878.md) | [(331)](/filings/0000950170-25-075374.md) | [(49.7)](/filings/0000950170-25-102561.md) | [(33.3)](/filings/0001193125-25-264157.md) | [(46.1)](/filings/0000950170-25-075366.md) | [(11.3)](/filings/0001193125-26-205276.md) | [(20.5)](/filings/0001193125-26-331632.md) | [(10.3)](/filings/0001193125-25-264157.md) | [(3.6) d](/filings/0001193125-26-073878.md) | [(1.3)](/filings/0001193125-26-205276.md) | [(10.9)](/filings/0001193125-26-331632.md) |
| Diluted EPS | $ per share | [(1.00)](/filings/0000950170-24-125685.md) | not reported | [(0.01)](/filings/0001193125-26-205276.md) | [(0.63)](/filings/0000950170-25-102561.md) | [(0.38)](/filings/0001193125-25-264157.md) | [(0.58)](/filings/0000950170-25-075366.md) | [(0.14)](/filings/0001193125-26-205276.md) | [(0.24)](/filings/0001193125-26-331632.md) | [(0.12)](/filings/0001193125-25-264157.md) | not reported | [(0.01)](/filings/0001193125-26-205276.md) | [(0.13)](/filings/0001193125-26-331632.md) |
| Basic EPS | $ per share | [(1.00)](/filings/0000950170-24-125685.md) | not reported | [(0.01)](/filings/0001193125-26-205276.md) | [(0.63)](/filings/0000950170-25-102561.md) | [(0.38)](/filings/0001193125-25-264157.md) | [(0.58)](/filings/0000950170-25-075366.md) | [(0.14)](/filings/0001193125-26-205276.md) | [(0.24)](/filings/0001193125-26-331632.md) | [(0.12)](/filings/0001193125-25-264157.md) | not reported | [(0.01)](/filings/0001193125-26-205276.md) | [(0.13)](/filings/0001193125-26-331632.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [116](/filings/0000950170-24-031690.md) | [87.2](/filings/0000950170-25-075366.md) | [107](/filings/0000950170-25-075374.md) | [111](/filings/0000950170-25-102561.md) | [88.5](/filings/0001193125-25-264157.md) | [76.0](/filings/0001193125-26-073878.md) | [101](/filings/0000950170-25-075374.md) | [106](/filings/0000950170-25-102561.md) | [93.7](/filings/0001193125-25-264157.md) | [95.7](/filings/0001193125-26-331632.md) | [88.3](/filings/0001193125-26-205276.md) | [79.2](/filings/0001193125-26-331632.md) |
| Current assets | $m | [780](/filings/0000950170-24-031690.md) | [719](/filings/0000950170-25-075366.md) | [688](/filings/0000950170-25-075374.md) | [656](/filings/0000950170-25-102561.md) | [630](/filings/0001193125-25-264157.md) | [599](/filings/0001193125-26-073878.md) | [612](/filings/0000950170-25-075374.md) | [607](/filings/0000950170-25-102561.md) | [603](/filings/0001193125-25-264157.md) | [635](/filings/0001193125-26-331632.md) | [634](/filings/0001193125-26-205276.md) | [618](/filings/0001193125-26-331632.md) |
| Total assets | $m | [1,742](/filings/0000950170-24-031690.md) | [1,677](/filings/0000950170-25-075366.md) | [1,327](/filings/0000950170-25-075374.md) | [1,286](/filings/0000950170-25-102561.md) | [1,267](/filings/0001193125-25-264157.md) | [1,171](/filings/0001193125-26-073878.md) | [1,193](/filings/0000950170-25-075374.md) | [1,216](/filings/0000950170-25-102561.md) | [1,209](/filings/0001193125-25-264157.md) | [1,204](/filings/0001193125-26-331632.md) | [1,185](/filings/0001193125-26-205276.md) | [1,150](/filings/0001193125-26-331632.md) |
| Current liabilities | $m | [285](/filings/0000950170-24-031690.md) | [274](/filings/0000950170-25-075366.md) | [285](/filings/0000950170-25-075374.md) | [288](/filings/0000950170-25-102561.md) | [310](/filings/0001193125-25-264157.md) | [293](/filings/0001193125-26-073878.md) | [303](/filings/0000950170-25-075374.md) | [310](/filings/0000950170-25-102561.md) | [308](/filings/0001193125-25-264157.md) | [362](/filings/0001193125-26-331632.md) | [359](/filings/0001193125-26-205276.md) | [345](/filings/0001193125-26-331632.md) |
| Total liabilities | $m | [625](/filings/0000950170-24-031690.md) | [629](/filings/0000950170-25-075366.md) | [623](/filings/0000950170-25-075374.md) | [629](/filings/0000950170-25-102561.md) | [639](/filings/0001193125-25-264157.md) | [622](/filings/0001193125-26-073878.md) | [631](/filings/0000950170-25-075374.md) | [645](/filings/0000950170-25-102561.md) | [665](/filings/0001193125-25-264157.md) | [685](/filings/0001193125-26-331632.md) | [679](/filings/0001193125-26-205276.md) | [661](/filings/0001193125-26-331632.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [676](/filings/0000950170-24-125685.md) | [605](/filings/0001193125-26-073878.md) | [261](/filings/0001193125-25-264157.md) | [214](/filings/0001193125-25-264157.md) | [206](/filings/0001193125-25-264157.md) | [127](/filings/0001193125-26-331632.md) | [139](/filings/0001193125-26-331632.md) | [170](/filings/0001193125-26-331632.md) | [142](/filings/0001193125-25-264157.md) | [146](/filings/0001193125-26-331632.md) | [138](/filings/0001193125-26-331632.md) | [129](/filings/0001193125-26-331632.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [6.8 d](/filings/0000950170-24-125685.md) | [(13.7) d](/filings/0001193125-26-073878.md) | [37.9](/filings/0000950170-25-075374.md) | [19.9 d](/filings/0000950170-25-102561.md) | [43.3 d](/filings/0001193125-25-264157.md) | [2.4 d](/filings/0001193125-26-073878.md) | [43.2](/filings/0001193125-26-205276.md) | [32.2 d](/filings/0001193125-26-331632.md) | [12.2 d](/filings/0001193125-25-264157.md) | [42.2 d](/filings/0001193125-26-073878.md) | [12.7](/filings/0001193125-26-205276.md) | [25.9 d](/filings/0001193125-26-331632.md) |
| Capital expenditure | $m | [13.6 d](/filings/0000950170-24-125685.md) | [2.7 d](/filings/0001193125-26-073878.md) | [13.5](/filings/0000950170-25-075374.md) | [11.5 d](/filings/0000950170-25-102561.md) | [6.2 d](/filings/0001193125-25-264157.md) | [3.3 d](/filings/0001193125-26-073878.md) | [7.4](/filings/0001193125-26-205276.md) | [4.7 d](/filings/0001193125-26-331632.md) | [8.0 d](/filings/0001193125-25-264157.md) | [11.7 d](/filings/0001193125-26-073878.md) | [7.5](/filings/0001193125-26-205276.md) | [8.9 d](/filings/0001193125-26-331632.md) |
| Dividends paid | $m | [7.1 d](/filings/0000950170-24-125685.md) | [0.0 d](/filings/0001193125-26-073878.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [78.4](/filings/0000950170-24-057628.md) | [78.4](/filings/0000950170-24-094602.md) | [78.4](/filings/0000950170-24-125685.md) | [80.3](/filings/0001193125-26-205276.md) | [78.9](/filings/0000950170-25-102561.md) | [79.0](/filings/0001193125-25-264157.md) | [79.1](/filings/0000950170-25-075366.md) | [79.5](/filings/0001193125-26-205276.md) | [79.7](/filings/0001193125-26-331632.md) | [79.8](/filings/0001193125-25-264157.md) | [80.3](/filings/0001193125-26-205276.md) | [80.9](/filings/0001193125-26-331632.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 81,481,407 at 2026-08-03, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-331632.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.